

CMS Measure ID/CMS QCDR ID: CAP 41 Measure Title: Basal Cell Skin Cancer: Complete Reporting

Measure Specifications

Measure Description	Percentage of final pathology reports for excisions for basal cell carcinoma of the skin that include a comment on histologic subtype, margin status, and if applicable to the specimen - invasion of tumor beyond reticular dermis (or level of invasion, for Moh's specimens), and perineural invasion
Denominator Statement	All final pathology reports for patients, regardless of age, who undergo an excision which include a diagnosis of malignant cutaneous basal cell carcinoma
	 CPT®1: 88305 (Excision including Moh's excisions) AND ICD10: C44.01 Basal cell carcinoma of skin of lip C44.111 Basal cell carcinoma of skin of unspecified eyelid, including canthus C44.1121 Basal cell carcinoma of skin of right upper eyelid, including canthus C44.1122 Basal cell carcinoma of skin of left upper eyelid, including canthus C44.1191 Basal cell carcinoma of skin of left lower eyelid, including canthus C44.1192 Basal cell carcinoma of skin of left lower eyelid, including canthus C44.211 Basal cell carcinoma of skin of left lower eyelid, including canthus C44.211 Basal cell carcinoma of skin of unspecified ear and external auricular canal C44.212 Basal cell carcinoma of skin of left ear and external auricular canal C44.219 Basal cell carcinoma of skin of left ear and external auricular canal C44.310 Basal cell carcinoma of skin of nose C44.310 Basal cell carcinoma of skin of other parts of face C44.310 Basal cell carcinoma of skin of scalp and neck C44.511 Basal cell carcinoma of skin of breast C44.511 Basal cell carcinoma of skin of other parts of face C44.611 Basal cell carcinoma of skin of other part of trunk C44.612 Basal cell carcinoma of skin of unspecified upper limb, including shoulder C44.612 Basal cell carcinoma of skin of left upper limb, including shoulder C44.714 Basal cell carcinoma of skin of left upper limb, including shoulder C44.714 Basal cell carcinoma of skin of left upper limb, including shoulder C44.714 Basal cell carcinoma of skin of right upper limb, including hip C44.714 Basal cell carcinoma of skin of left upper limb, including hip C44.714 Basal cell carcinoma of skin of right upper limb, including hip C44.719 Basal cell carcinoma of skin of right lower limb, including hip C44.719 Basal cell carcinoma of skin of right lower limb, includi
Denominator Exclusions	 Specimens that are exclusively in situ disease (ICD10 D04.0, D04.10, D04.111, D04.112, D04.121, D04.122, D04.20, D04.21, D04.22, D04.30, D04.39, D04.4, D04.5, D04.60, D04.61, D04.62, D04.70, D04.71, D04.72, D04.8, D04.9)

¹ CPT copyright: 2023 American Medical Association. All rights reserved.

Last Updated: 12/04/2023

Page 1 of 3 © College of American Pathologists. All rights reserved. The College of American Pathologists (CAP) owns all rights, title, and interests in this quality measure. This quality measure is provided solely for the benefit of CAP, its members and the Pathologists Quality Registry for the purposes specified herein and for other CAP purposes. It may not be used by other parties except with prior written approval of the CAP. Email measures@cap.org for more information.



COLLEGE of AMERICAN PATHOLOGISTS

Denominator Exceptions	 Cytology specimens Specimens displaying fragmentation No residual carcinoma Necrotic tissue Specimen site other than cutaneous or cancer other than basal cell Pathology report contains a statement on the following: 	
Statement	 Margin status Histologic Type If applicable to the specimen, Invasion beyond the reticular dermis or for Mohs' excisions, level of invasion Presence of perineural invasion 	
Numerator Exclusions	None	
Measure Information		
NQS Domain	Communication and Care Coordination	
Meaningful Measures Area(s)	Transfer of Health Information and Interoperability	
Meaningful Measure Rationale	 The data elements included in this measure are critical for determining the risk for local recurrence or metastasis in patients with cutaneous basal cell carcinoma (1). Communication of this information to the dermatologist is essential for establishing treatment options and follow-up including monitoring high-risk cancers for progression (2). 1. NCCN Clinical Practice Guidelines in Oncology (2022) Basal Cell Skin Cancer. Version 2.2022, published online march 24,, 2022 at https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf 	
Measure Type	Process	
Data Source	Laboratory Information Systems; pathology reports	
Summary of Performance Gap Evidence	N/A	
Measure Owner	College of American Pathologists	
NQF ID	N/A	
Number of Performance Rates	1	

Last Updated: 12/04/2023

Page 2 of 3 © College of American Pathologists. All rights reserved. The College of American Pathologists (CAP) owns all rights, title, and interests in this quality measure. This quality measure is provided solely for the benefit of CAP, its members and the Pathologists Quality Registry for the purposes specified herein and for other CAP purposes. It may not be used by other parties except with prior written approval of the CAP. Email measures@cap.org for more information.



Overall Performance Rate	1st Performance Rate
High-priority	Yes
Improvement Notation	Inverse Measure: No Proportional Measure: Yes (Higher score indicates better quality) Continuous Variable Measure: No Ratio Measure: No Risk-adjusted: No
Care Setting and Specialty	Care Setting: Other—Laboratories; Telehealth not applicable Specialty: Pathology
Current Clinical Guideline the Measure is Derived From	https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf